Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma

Status Recruiting

Clinical Trial Summary

This study is an open and prospective clinical study, taking patients with relapsed or refractory CD7+ lymphoma as the test subjects, in order to evaluate the safety and efficacy of Senl-T7 CAR-T for patients with CD7+ lymphoma.

Clinical Trial Description

Main research purposes: To evaluate the safety and efficacy of Senl-T7 CAR-T for relapsed or refractory CD7+ lymphoma Secondary research purpose: To investigate the cytokinetic characteristics of Senl-T7 CAR-T for relapsed or refractory CD7+ lymphoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04928105
Study type	Interventional
Source	Hebei Senlang Biotechnology Inc., Ltd.
Contact	Peihua MD Lu, PhD
Phone	008618611636172
Email	peihua_lu@126.com
Status	Recruiting
Phase	N/A
Start date	January 27, 2021
Completion date	March 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05540340` - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant	Phase 1
Completed	`NCT02158975` - Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas	Phase 2
Completed	`NCT00043368` - PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)	Phase 2
Completed	`NCT00069238` - Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas	Phase 2
Recruiting	`NCT04104776` - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas	Phase 1/Phase 2
Active, not recruiting	`NCT03703375` - Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma	Phase 3
Recruiting	`NCT05476770` - Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies	Phase 1
Completed	`NCT00038376` - Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies	Phase 2
Recruiting	`NCT03161223` - Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03902184` - IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma	Phase 2
Recruiting	`NCT05398614` - SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies	Phase 1
Not yet recruiting	`NCT03910283` - Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer	N/A
Completed	`NCT04121507` - ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy	Phase 2
Completed	`NCT04136275` - CAR-37 T Cells In Hematologic Malignancies	Phase 1
Recruiting	`NCT03921879` - Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma	Phase 1
Terminated	`NCT03154710` - Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response	N/A
Recruiting	`NCT05466318` - ChiCGB vs BEAM in High-risk or R/R Lymphomas	Phase 3
Withdrawn	`NCT04233697` - Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma	Phase 1
Completed	`NCT01309789` - A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms	Phase 1
Recruiting	`NCT05557903` - Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL	Phase 1